FDI-6
Based on 6 publication(s) in Google Scholar
FDI-6 is an inhibitor of FOXM1. FDI-6 binds directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.60%
- No. CAS: 313380-27-7
- Fòrmula: C19H11F4N3OS2
- Peso molecular:437.43
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) FDI-6
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
Ver todos los productos específicos de isoformas DNA/RNA Synthesis
More
Actividad biológica
FOXM1[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
86.14 μM
Compound: FDI6
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 22 to 70 hrs by CCK-8 assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 22 to 70 hrs by CCK-8 assay
|
[PMID: 36334454] |
| HepG2 | IC50 |
70.5 μM
Compound: FDI6
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 22 to 70 hrs by CCK-8 assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 22 to 70 hrs by CCK-8 assay
|
[PMID: 36334454] |
| MDA-MB-231 | GI50 |
25.6 μM
Compound: FDI-6
|
Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay
|
[PMID: 34812040] |
| SK-OV-3 | IC50 |
51.36 μM
Compound: FDI6
|
Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 22 to 70 hrs by CCK-8 assay
Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 22 to 70 hrs by CCK-8 assay
|
[PMID: 36334454] |
FDI-6 is characterized in depth and is shown to bind directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation. MDA-MB-231 ER-negative breast and PEO-1 ovarian cancer cells are sensitive to FDI-6 in cell viability assays (GI50=21.8 μM and 18.1 μM, respectively) and exhibit comparable down-regulation of CDC25B after a 3 h treatment with FDI-6. The transcription factor FOXM1 regulates a network of proliferation-associated genes critical to mitotic spindle assembly, chromosome segregation, and G2/M transition, with depletion leading to cell cycle arrest. Importantly, aberrant up-regulation of FOXM1 has been shown to be a key driver of cancer progression and has been proposed as an initiating factor of oncogenesis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 313380-27-7
-
Appearance Solid
-
Peso molecular 437.43
-
Fòrmula C19H11F4N3OS2
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C(N)C2=C(C(F)(F)F)C=C(C3=CC=CS3)N=C2S1)NC4=CC=C(F)C=C4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
2025 Jul 15;85(14):2714-2725. PMID: 40293223 -
Cancer Res
Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer. [Abstract]2024 Nov 4;84(21):3556-3573. PMID: 39037997
FDI-6 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Nov 4;84(21):3556-3573. [Abstract]
PTXR MDA-MB-231 cells were treated with vehicle (DMSO), 5μM FDI-6 (FOXM1i), 25nM paclitaxel (PTX) or both drugs (COMBO). Relative cell number was assessed by measuring cell confluency using the Sartorius Incucyte for up to 120 hours. PTXR MDA-MB-231 cells were treated with vehicle, FOXM1i (5 μM), PTX (10 nM), or the combination (COMBO) for 72 hr.
-
Mol Syst Biol
2025 Sep;21(9):1263-1281. PMID: 40588571 -
Transl Oncol
Thiostrepton suppresses intrahepatic cholangiocarcinoma progression via FOXM1-mediated tumor-associated macrophages reprogramming. [Abstract]2025 Feb 21:54:102327. PMID: 39986191
FDI-6 purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Feb 21:54:102327. [Abstract]
The half-maximal inhibitory concentrations (IC50) of TST, SioA, RCM-1, and FDI-6 were determined after a 24-hour treatment in CCLP-1 cells.
-
Cancers (Basel)
Characterizing and Targeting Genes Regulated by Transcription Factor MYBL2 in Lung Adenocarcinoma Cells. [Abstract]2022 Oct 11;14(20):4979. PMID: 36291764
FDI-6 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2022 Oct 11;14(20):4979. [Abstract]
A structure of FDI-6 (left). A549 and NCI-H2126 cells were counted every 24 h after treatment with different concentrations of FDI-6 (0-20 μM) for 72 h.
FDI-6 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2022 Oct 11;14(20):4979. [Abstract]
Colony formation images of A549 and NCI-H2126. A549 and NCI-H2126 cells after being treated with FDI-6 (0-20 μM) for 24 h and then incubated for 14 days.
FDI-6 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2022 Oct 11;14(20):4979. [Abstract]
A volcano plot demonstrating differential gene expression after treatment of FDI-6 in A549 cells. X-axis shows the log2 fold change between FDI-6 treated and untreated cells, and Y-axis shows the −log2(adjusted p-value) upon the comparison between FDI-6 treated and untreated cells.
-
Solvente y solubilidad
DMSO : 41.67 mg/mL (95.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.72 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2861 mL | 11.4304 mL | 22.8608 mL | 57.1520 mL |
| 5 mM | 0.4572 mL | 2.2861 mL | 4.5722 mL | 11.4304 mL | |
| 10 mM | 0.2286 mL | 1.1430 mL | 2.2861 mL | 5.7152 mL | |
| 15 mM | 0.1524 mL | 0.7620 mL | 1.5241 mL | 3.8101 mL | |
| 20 mM | 0.1143 mL | 0.5715 mL | 1.1430 mL | 2.8576 mL | |
| 25 mM | 0.0914 mL | 0.4572 mL | 0.9144 mL | 2.2861 mL | |
| 30 mM | 0.0762 mL | 0.3810 mL | 0.7620 mL | 1.9051 mL | |
| 40 mM | 0.0572 mL | 0.2858 mL | 0.5715 mL | 1.4288 mL | |
| 50 mM | 0.0457 mL | 0.2286 mL | 0.4572 mL | 1.1430 mL | |
| 60 mM | 0.0381 mL | 0.1905 mL | 0.3810 mL | 0.9525 mL | |
| 80 mM | 0.0286 mL | 0.1429 mL | 0.2858 mL | 0.7144 mL |
FDI-6 Related Classifications
HY-112721 Related Classifications
Powered by Bioz